LitCovid-sentences  

PMC:7534795 / 39597-46304 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T285 0-82 Sentence denotes Pharmacological intervention Sample size and criteria Treatment protocol Reference
T286 83-99 Sentence denotes • TACTIC-E Trial
T287 100-154 Sentence denotes • Immunomodulatory agents • Multi-arm randomized trial
T288 155-204 Sentence denotes • Pre-intensive care unit (ICU) COVID-19 patients
T289 205-286 Sentence denotes • Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care
T290 287-423 Sentence denotes • Primary outcome includes need for cardiovascular organ support • EDP1815 as 2 capsules twice daily (1.6 × 1011 cells) for up to 7 days
T291 424-495 Sentence denotes • Dapagliflozin 10 mg + ambrisentan 5 mg once daily (NCT04393246, 2020)
T292 496-649 Sentence denotes • High dose IV Vitamin C to ameliorate cytokine storm and associated organ dysfunction • Prospective placebo controlled randomized controlled trial (RCT)
T293 650-660 Sentence denotes • N = 308
T294 661-706 Sentence denotes • High dose i.v. vitamin C (HIVC) vs. placebo
T295 707-904 Sentence denotes • Primary outcome of ventilator-free days • 12 g/50 ml vitamin C infusion 12 ml/h twice daily for 7 days vs. 50 ml sterile water for injection infused at 12 ml/h (Liu, Zhu, Zhang, Li, & Peng, 2020)
T296 905-959 Sentence denotes • TOC-COVID Trial • Prospective placebo controlled RCT
T297 960-1002 Sentence denotes • N = 100 tocilizumab + standard treatment
T298 1003-1042 Sentence denotes • N = 100 placebo + standard treatment
T299 1043-1148 Sentence denotes • Primary outcome of ventilation-free days • Tocilizumab 8 mg/kg single i.v. dose (Rilinger et al., 2020)
T300 1149-1165 Sentence denotes • TACTIC-R Trial
T301 1166-1236 Sentence denotes • Immunomodulatory agents • Randomized parallel 3-arm open label trial
T302 1237-1259 Sentence denotes • N = 125 Baricitinib
T303 1260-1282 Sentence denotes • N = 125 Ravulizumab
T304 1283-1309 Sentence denotes • N = 125 standard of care
T305 1310-1424 Sentence denotes • Primary outcome includes need for cardiovascular organ support • Baricitinib 4 mg orally once daily on days 1–14
T306 1425-1500 Sentence denotes • Ravulizumab single i.v. weight-based dose regimen (Kulkarni et al., 2020)
T307 1501-1517 Sentence denotes • CytoResc Trial
T308 1518-1604 Sentence denotes • Cytokine storm in hyperinflammation and shock • Prospective, open-label, pilot study
T309 1605-1680 Sentence denotes • ‘CytoSorb’ polystyrene-based hemoadsorber to adsorb circulating cytokines
T310 1681-1704 Sentence denotes • N = 40–50 ‘CytoSorb’
T311 1705-1730 Sentence denotes • N = 40–50 standard care
T312 1731-1885 Sentence denotes • Primary outcome is time to resolution of vasoplegic shock • ‘CytoSorb’ therapy administered via a shaldon catheter for 3–7 days (Stockmann et al., 2020)
T313 1886-1940 Sentence denotes • MelCOVID Trial • Double blind placebo controlled RCT
T314 1941-1964 Sentence denotes • ICU COVID-19 patients
T315 1965-2002 Sentence denotes • N = 12 melatonin + standard of care
T316 2003-2043 Sentence denotes • N = 6 placebo control + standard care
T317 2044-2147 Sentence denotes • Secondary outcome includes CRP, IL-6 levels • Melatonin 5 mg/kg/day i.v. divided every 6 h for 7 days
T318 2148-2242 Sentence denotes • Placebo dose of 5 mg/kg/day i.v. divided every 6 h for 7 days (Rodriguez-Rubio et al., 2020)
T319 2243-2332 Sentence denotes • Siltuximab for patients diagnosed with severe respiratory complications due to COVID-19
T320 2333-2416 Sentence denotes • Anti-IL-6 mitigation of cytokine storm • Observational retrospective cohort study
T321 2417-2487 Sentence denotes • Cohort A: continuous positive airway pressure followed by siltuximab
T322 2488-2533 Sentence denotes • Cohort B: intubation followed by siltuximab
T323 2534-2614 Sentence denotes • Control group receiving continuous positive airway pressure or intubation only
T324 2615-2625 Sentence denotes • N = 220
T325 2626-2721 Sentence denotes • Primary outcome of mortality over 30 days • Detailed siltuximab dosing regimen not specified.
T326 2722-2777 Sentence denotes • Treatment procedure was based on clinicians judgement
T327 2778-2808 Sentence denotes • Study completed May 8, 2020.
T328 2809-2844 Sentence denotes Results pending (NCT04322188, 2020)
T329 2845-2860 Sentence denotes • COV-AID Trial
T330 2861-2938 Sentence denotes • Use of anti-interleukin agents for cytokine storm • Phase 3 prospective RCT
T331 2939-2978 Sentence denotes • Patients with signs of cytokine storm
T332 2979-3023 Sentence denotes • N = 38 Anakinra alone (anti-IL-1 receptor)
T333 3024-3062 Sentence denotes • N = 76 Siltuximab alone (anti-IL-6)
T334 3063-3094 Sentence denotes • N = 38 Anakinra + siltuximab
T335 3095-3142 Sentence denotes • N = 76 Tocilizumab alone (anti-IL-6 receptor)
T336 3143-3174 Sentence denotes • N = 38 Anakinra + tocilizumab
T337 3175-3203 Sentence denotes • N = 76 standard care alone
T338 3204-3294 Sentence denotes • Primary outcome as time to clinical improvement • Anakinra 100 mg s.c. daily for 28 days
T339 3295-3337 Sentence denotes • Siltuximab single i.v. infusion 11 mg/kg
T340 3338-3411 Sentence denotes • Tocilizumab single i.v. infusion 8 mg/kg max 800 mg (Maes et al., 2020)
T341 3412-3460 Sentence denotes • Sarilumab for hospitalized COVID-19 infections
T342 3461-3502 Sentence denotes • Cytokine storm syndrome • Phase 2/3 RCT
T343 3503-3513 Sentence denotes • Phase 2:
T344 3514-3591 Sentence denotes Sarilumab in hospitalized patients regardless of disease severity vs. placebo
T345 3592-3677 Sentence denotes • Primary outcome of % change in CRP in patients with serum IL-6 > upper limit normal
T346 3678-3697 Sentence denotes • Phase 3 Cohort 1:
T347 3698-3787 Sentence denotes Sarilumab in hospitalized critical infection receiving mechanical ventilation vs. placebo
T348 3788-3799 Sentence denotes • Cohort 2:
T349 3800-3880 Sentence denotes Sarilumab in hospitalized infection receiving mechanical ventilation vs. placebo
T350 3881-3892 Sentence denotes • N = 1912
T351 3893-3979 Sentence denotes • Primary outcome of at least 1 point improvement on 7 point clinical scale • Phase 2:
T352 3980-4003 Sentence denotes Low dose sarilumab i.v.
T353 4004-4014 Sentence denotes • Phase 2:
T354 4015-4038 Sentence denotes Mid-dose sarilumab i.v.
T355 4039-4058 Sentence denotes • Phase 3 Cohort 1:
T356 4059-4082 Sentence denotes Low dose sarilumab i.v.
T357 4083-4102 Sentence denotes • Phase 3 Cohort 1:
T358 4103-4126 Sentence denotes Mid-dose sarilumab i.v.
T359 4127-4146 Sentence denotes • Phase 3 Cohort 2:
T360 4147-4171 Sentence denotes High dose sarilumab i.v.
T361 4172-4241 Sentence denotes • Placebo given to match sarilumab administration (NCT04315298, 2020)
T362 4242-4263 Sentence denotes • CORIMUNO-SARI Trial
T363 4264-4318 Sentence denotes • Sarilumab to mitigate enhanced IL-6 signalling • RCT
T364 4319-4369 Sentence denotes • Moderate, severe, or critical COVID-19 pneumonia
T365 4370-4402 Sentence denotes • Sarilumab vs. standard of care
T366 4403-4491 Sentence denotes • N = 239 • Sarilumab 400 mg single i.v. infusion over 1 h on day 1 (NCT04324073, 2020)
T367 4492-4571 Sentence denotes • Barcitinib for hospitalized COVID-19 patients • Non-randomized clinical trial
T368 4572-4634 Sentence denotes • Any adult patient hospitalized with moderate/severe COVID-19
T369 4635-4687 Sentence denotes • Barcitinib + standard care vs. standard care alone
T370 4688-4801 Sentence denotes • Primary outcome of clinical status after 15 days • Barcitinib 2 mg orally daily for 10 days (NCT04321993, 2020)
T371 4802-4851 Sentence denotes • RUXCOVID Trial • Phase 3 placebo-controlled RCT
T372 4852-4891 Sentence denotes • Patients age ≥ 12 with cytokine storm
T373 4892-4949 Sentence denotes • Ruxolitinib + standard care vs. placebo + standard care
T374 4950-4984 Sentence denotes • N = 402 randomized in 2:1 ratio
T375 4985-5055 Sentence denotes • treatment: placebo • Ruxolitinib 5 mg orally twice daily for 14 days
T376 5056-5109 Sentence denotes • May extend treatment to 28 days (NCT04362137, 2020)
T377 5110-5178 Sentence denotes • Losartan (ARB) in patients hospitalized for COVID-19 • Phase 2 RCT
T378 5179-5217 Sentence denotes • Losartan vs. placebo + standard care
T379 5218-5228 Sentence denotes • N = 200
T380 5229-5353 Sentence denotes • Secondary outcome includes cardiovascular organ failure/dysfunction • Losartan 50 mg orally once daily (NCT04312009, 2020)
T381 5354-5439 Sentence denotes • Losartan (ARB) in patients not requiring hospitalization for COVID-19 • Phase 2 RCT
T382 5440-5478 Sentence denotes • Losartan vs. placebo + standard care
T383 5479-5489 Sentence denotes • N = 500
T384 5490-5627 Sentence denotes • Primary outcome of patients admitted to hospital within 15 days of randomization • Losartan 25 mg orally once daily (NCT04311177, 2020)
T385 5628-5739 Sentence denotes • Eicosapentaenoic acid (EPA) free fatty acid for hospitalized COVID-19 patients • Phase 3 interventional trial
T386 5740-5804 Sentence denotes • Treatment with EPA gastro-resistant capsules vs. standard care
T387 5805-5830 Sentence denotes • 28-day treatment period
T388 5831-5949 Sentence denotes • Primary outcome of time to treatment failure i.e. need for additional therapy, intubation, transfer to ICU, or death
T389 5950-6127 Sentence denotes • Secondary outcome includes reduction of IL-6 levels • Eicosapentaenoic acid free fatty acid (EPA-FFA) 1 g gastro-resistant capsules twice daily (2 g total) (NCT04335032, 2020)
T390 6128-6145 Sentence denotes • COLCORONA Trial
T391 6146-6266 Sentence denotes • Colchicine and inflammatory cytokine storm • Phase 3 multi-centre placebo-controlled randomized controlled trial (RCT)
T392 6267-6290 Sentence denotes • Age 40 years or older
T393 6291-6432 Sentence denotes • Patients must have at least one high-risk factor i.e. uncontrolled hypertension, HF, coronary artery disease (CAD), diabetes, obesity, etc.
T394 6433-6457 Sentence denotes • Colchicine vs. placebo
T395 6458-6476 Sentence denotes • 30-day treatment
T396 6477-6488 Sentence denotes • N = 6000
T397 6489-6640 Sentence denotes • Primary composite endpoint of need for hospitalization or death • Colchicine 0.5 mg orally twice daily for 3 days, then 0.5 mg once daily for 27 days
T398 6641-6707 Sentence denotes • Placebo will match colchicine administration (NCT04322682, 2020)